Cargando…

Functional characterization of SOX2 as an anticancer target

SOX2 is a well-characterized pluripotent factor that is essential for stem cell self-renewal, reprogramming, and homeostasis. The cellular levels of SOX2 are precisely regulated by a complicated network at the levels of transcription, post-transcription, and post-translation. In many types of human...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shizhen, Xiong, Xiufang, Sun, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391717/
https://www.ncbi.nlm.nih.gov/pubmed/32728033
http://dx.doi.org/10.1038/s41392-020-00242-3
_version_ 1783564706771894272
author Zhang, Shizhen
Xiong, Xiufang
Sun, Yi
author_facet Zhang, Shizhen
Xiong, Xiufang
Sun, Yi
author_sort Zhang, Shizhen
collection PubMed
description SOX2 is a well-characterized pluripotent factor that is essential for stem cell self-renewal, reprogramming, and homeostasis. The cellular levels of SOX2 are precisely regulated by a complicated network at the levels of transcription, post-transcription, and post-translation. In many types of human cancer, SOX2 is dysregulated due to gene amplification and protein overexpression. SOX2 overexpression is associated with poor survival of cancer patients. Mechanistically, SOX2 promotes proliferation, survival, invasion/metastasis, cancer stemness, and drug resistance. SOX2 is, therefore, an attractive anticancer target. However, little progress has been made in the efforts to discover SOX2 inhibitors, largely due to undruggable nature of SOX2 as a transcription factor. In this review, we first briefly introduced SOX2 as a transcription factor, its domain structure, normal physiological functions, and its involvement in human cancers. We next discussed its role in embryonic development and stem cell-renewal. We then mainly focused on three aspects of SOX2: (a) the regulatory mechanisms of SOX2, including how SOX2 level is regulated, and how SOX2 cross-talks with multiple signaling pathways to control growth and survival; (b) the role of SOX2 in tumorigenesis and drug resistance; and (c) current drug discovery efforts on targeting SOX2, and the future perspectives to discover specific SOX2 inhibitors for effective cancer therapy.
format Online
Article
Text
id pubmed-7391717
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73917172020-08-12 Functional characterization of SOX2 as an anticancer target Zhang, Shizhen Xiong, Xiufang Sun, Yi Signal Transduct Target Ther Review Article SOX2 is a well-characterized pluripotent factor that is essential for stem cell self-renewal, reprogramming, and homeostasis. The cellular levels of SOX2 are precisely regulated by a complicated network at the levels of transcription, post-transcription, and post-translation. In many types of human cancer, SOX2 is dysregulated due to gene amplification and protein overexpression. SOX2 overexpression is associated with poor survival of cancer patients. Mechanistically, SOX2 promotes proliferation, survival, invasion/metastasis, cancer stemness, and drug resistance. SOX2 is, therefore, an attractive anticancer target. However, little progress has been made in the efforts to discover SOX2 inhibitors, largely due to undruggable nature of SOX2 as a transcription factor. In this review, we first briefly introduced SOX2 as a transcription factor, its domain structure, normal physiological functions, and its involvement in human cancers. We next discussed its role in embryonic development and stem cell-renewal. We then mainly focused on three aspects of SOX2: (a) the regulatory mechanisms of SOX2, including how SOX2 level is regulated, and how SOX2 cross-talks with multiple signaling pathways to control growth and survival; (b) the role of SOX2 in tumorigenesis and drug resistance; and (c) current drug discovery efforts on targeting SOX2, and the future perspectives to discover specific SOX2 inhibitors for effective cancer therapy. Nature Publishing Group UK 2020-07-29 /pmc/articles/PMC7391717/ /pubmed/32728033 http://dx.doi.org/10.1038/s41392-020-00242-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Zhang, Shizhen
Xiong, Xiufang
Sun, Yi
Functional characterization of SOX2 as an anticancer target
title Functional characterization of SOX2 as an anticancer target
title_full Functional characterization of SOX2 as an anticancer target
title_fullStr Functional characterization of SOX2 as an anticancer target
title_full_unstemmed Functional characterization of SOX2 as an anticancer target
title_short Functional characterization of SOX2 as an anticancer target
title_sort functional characterization of sox2 as an anticancer target
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391717/
https://www.ncbi.nlm.nih.gov/pubmed/32728033
http://dx.doi.org/10.1038/s41392-020-00242-3
work_keys_str_mv AT zhangshizhen functionalcharacterizationofsox2asananticancertarget
AT xiongxiufang functionalcharacterizationofsox2asananticancertarget
AT sunyi functionalcharacterizationofsox2asananticancertarget